Form 4: Johnson & Johnson Executive VP, CFO Joseph Wolk Reports Stock Option Exercise and Sale

Executive VP and CFO of Johnson & Johnson, Joseph Wolk, reports exercising stock options and selling shares on February 7, 2025.

Summary

• On February 7, 2025, Joseph Wolk, Executive VP and CFO of Johnson & Johnson, exercised employee stock options for 13,015 shares of common stock at a price of $100.06 per share.
• Immediately following the exercise, Wolk sold the 13,015 shares at a weighted average price of $153.89 per share, with individual trades ranging from $153.86 to $153.97.
• After the reported transactions, Wolk directly owns no shares of Johnson & Johnson common stock.
• Wolk indirectly owns 68,835 shares through a spousal lifetime access trust (SLAT) and 2,113 shares through a 401k plan, which includes shares accrued due to dividend reinvestment as of January 31, 2025.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives who receive stock options as part of their compensation. The information is publicly available and helps ensure transparency in the market.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The exercise and sale of these options are standard practice and are usually disclosed through Form 4 filings with the SEC.
• Comparable companies such as Pfizer (PFE) and Merck (MRK) also have executives who regularly report similar transactions.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders as it is a routine executive stock transaction.

Key Dates

Keywords

Form 4, insider trading, stock options, JNJ, Johnson & Johnson, Joseph Wolk, CFO, Executive VP, stock sale, beneficial ownership